Schering-Plough

(SGP)

said a clinical study of its drug Posaconazole showed it was successful in treating a wide variety of fungal infections.

The results of the study were presented at the 44th annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, D.C., on Sunday.

The drugmaker said Posaconazole may also have broad clinical use in the treatment of infections when other therapies have failed.

Life-threatening fungal infections occur in patients with severely weakened immune systems, including those who have had organ transplants or are undergoing chemotherapy, according to the company.

Shares fell 50 cents, or 2.8%, to $17.61.